Chairman Andy Grove told Forbes he is making a $40 million bequest to the Michael J.Fox Foundation for Parkinson's Research to help it continue pushing for a cure to theneurological disease.

Grove, 71, was diagnosed with Parkinson's in 2000. Since then, he has spent orcommitted to spend $22 million on further research and treatments for the disease.Some of those funds have been spent in conjunction with the Michael J. FoxFoundation, to which Grove serves as an adviser. The additional $40 million that hewill contribute posthumously to the foundation underscores his support. "This is a vote of confidence from me," says Grove. "It actually makes my livingcollaboration more productive."

The foundation was established by the actor Michael J. Fox, who was diagnosed withParkinson's in 1991 when he was just 30 years old. Grove has been increasingly active in raising money for scientific research over the pastdecade. He spent seven years spearheading a fundraising campaign for scientificresearch at the University of California, San Francisco, which garnered $1.6 billion incontributions. Forbes has estimated Grove's personal net worth at about $400 million.Both Grove and the Fox Foundation are impatient with the slow progress in developingnew drugs for Parkinson's. The mainstay drug, levadopa, is 40 years old, and merelyaddresses the symptoms of Parkinson's. No drug is available to slow the progress ofParkinson's disease, which affects 6 million people worldwide. The National Institutesof Health spends $200 million a year on Parkinson's research, but scientists still don'tknow what causes the disease.

Over the past few years, Grove has applied his characteristic intensity and razor-sharpintellect to exploring why progress in finding treatments for neurological diseases, suchas Parkinson's, has been agonizingly slow.

"What is needed is a cultural revolution that values curiosity, follow-through aproblem-solving orientation" as well as one that puts the data collected by scientistsunder broad scrutiny, Grove said in a speech in November to the annual conference ofthe Society for Neuroscience. (See the Jan. 28 issue of Forbes magazine for a detailedexploration of his campaign.)

Grove found kindred spirits in those who run the Michael J. Fox Foundation. Since itwas launched in 2000, the Michael J. Fox Foundation has spent $100 million fundingresearch focused on better treatments and--it hopes--a cure. "Patient relevance iscentral to every decision we make. We fund research that pushes things along," saysKatie Hood, chief executive of the Fox Foundation.

The Fox Foundation has also become a powerful arbiter of emerging treatments forParkinson's. Edward Lanphier, chief executive of Sangamo BioSciences (nasdaq: SGMO - news - people ), beams when he tells a reporter that his company has a $1million grant from the Fox Foundation for a new Parkinson's treatment that has yet toenter clinical trials.

Others wish they had that stamp of approval. "People ask us why we don't havefunding from Michael J. Fox," says John Mordock, chief of Neurologix (otcbb: NRGX.OB - news - people ), a biotech company that has completed an early stagegene therapy trial for Parkinson's.

These days, Grove exhibits few signs of Parkinson's other than an occasional tremor inhis right hand. He exercises religiously with the hope that it will help stave offprogression of the disease. And while he still serves as a senior adviser to Intel (nasdaq:INTC - news - people ) management, Grove spends around half his time delving intothe details of the Parkinson's research he is funding.